1. CUBIST SEEKS CALIXA IN ANTIBIOTIC PUSH.
- Author
-
M. M.
- Subjects
- *
PHARMACEUTICAL industry mergers , *LEAD compounds , *ANTIBIOTICS , *BETA lactamases , *TAZOBACTAM , *MARKETING - Abstract
The article reports on the acquisition of privately held Calixa Therapeutics Inc. by Cubist Pharmaceuticals Inc. for 92.5 million dollars in cash. It says that the agreement includes the possible additional payments of up to 310 million dollars which will depend on the performance of Calixa's lead compound, CXA-201. The compound is a mixture of CXA-101 and the β-lactamase inhibitor tazobactam. Moreover, Cubist already markets daptomycin, the first lipopeptides, a new class of antibiotics.
- Published
- 2009